biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > anyone else hearing

<< Previous

Bullboard Posts

Next >>

Comment by JDavenporton Oct 30, 2022 1:18pm

193 Views

Post# 35058575

RE:anyone else hearing

If something like that is imminent then one must wonder whether no deals have been allowed to happen during the "negotiation" period. In other words, would the pharma require Bioasis to enter no agreements until buyout terms are "negotiated," a word that I put in quotation markes for obvious reasons.

Imagine, a deal for all of Bioasis for less than what xB3-001 is worth.

Like I've been saying, watch out for the AGM information circular with an agenda asking for a management mandate to do whatever they want.

Black helicopters?

whoop, whoop, whoop, whoop, whoop, whoop...

jd

<< Previous

Bullboard Posts

Next >>

From now on, dynaCERT instead of Bitcoin or NVIDIA?